William Paris

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Bessemer Venture Partners LP seeks investment opportunities in companies primarily located in the US. The fund focuses on companies with a strong business model, experienced management teams and growth potential. It targets companies operating across a broad range of sectors such as healthcare, information systems, telecommunications, and retailing. It provides financing for seed, early and later stage capital requirements.

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA.

Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin.

Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors.

Brandon Point Industries Ltd. operates as a life sciences company. It focuses on healthcare. The company was founded in 2014 by George Kelly Martin and John Oliver Thomas Given and is headquartered in Dublin, Ireland.

Blueberry Therapeutics Ltd. engages in the development of innovative medicines. It offers nanomedicine, anti infection and anti microbial, anti inflammatory bowel diseases, acne, dermatitis and wound medicines. The company was founded by John Ridden and Mike Davies and is headquartered in Macclesfield, the United Kingdom.

Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom.

Excision BioTherapeutics, Inc. develops gene editing therapeutics for the treatment of life-threatening disease caused by viral infections. The firm focuses on Human Immunodeficiency Virus -1 therapeutics, JC Virus and Progressive Multifocal Leukoencephalopathy, Hepatitis B virus therapeutics, and CRISPR vaccinations?. The company was founded by David Rowe, Kamel Khalili, Thomas Malcolm, and Rob Simmons in 2015 and is headquartered in San Francisco, CA.

Prime Movers Lab LLC (Prime Movers Lab) is a venture capital firm founded in 2018 by Dakin Sloss. The firm is headquartered in Jackson, Wyoming.

Mirror Biologics Inc manufactures immune modulatory vaccines and therapeutics. The company is based in Tampa, FL. The company was founded in 2019 by Michael Har-Noy. Michael Har-Noy has been the CEO since 2019.